-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Galectin Therapeutics at Buy, Announces Price Target of $6

Benzinga·06/17/2025 11:26:12
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis assumes Galectin Therapeutics (NASDAQ:GALT) with a Buy rating and announces Price Target of $6.